Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 93 OC42 | DOI: 10.1530/endoabs.93.OC42

1University Hospital of Zurich, Endocrinology, Zürich, Switzerland 2University Hospital of Zurich, Nuclear Medicine, Switzerland.


Background: The combination of a toxic adenoma and Graves’ disease compose the Marine-Lenhart syndrome. It is estimated to occur in 0.8–2.7% of Graves’ disease and only few are reported.

Case presentation: A 29-year old female was referred to our clinic due to subclinical hyperthyroidism and a newly discovered thyroid nodule on the right thyroid lobe. She had no thyreotoxic symptoms and the clinical examination was unremarkable. The blood tests showed: TSH 0.01 mU/l (reference 0.16–4.25 mU/l), fT3 8.3 pmol/l, (reference 3.6–6.4 pmol/l), fT4 15.6 pmol/l (reference 12.3–20.2 pmol/l) and TSH-Receptor-Ab titers < 0.30 U/l (reference < 1.75 U/l). The thyroid ultrasound and scintigraphy revealed a toxic adenoma in a right sided goiter. Following a radioiodine ablation with 200 MBq 131-I was performed. Follow-up ultrasound after six months revealed a 70%-volume reduction of the formerly toxic adenoma of (2.6 ml, pre-therapy 8.7 ml). Two months later at the regular after-therapy follow-up, a manifest hyperthyroidism was revealed [TSH 0.004 mU/l, fT3 28.1 pmol/l and fT4 21.4 pmol/l] and the TSH-Receptor-Ab titers were elevated [1.85 U/l], while the patient was asymptomatic. A new thyroid scintigraphy showed a symmetrical, elevated uptake, leading to the diagnosis of Graves’ disease. A thyrostatic therapy with carbimazole was initiated for 8 months, until the thyroid function markers were normalised.

Conclusions: The co-existence of both a toxic adenoma and a Graves’ disease is termed Marine-Lenhart syndrome. It may be observed simultaneously or in different stages, according to the bibliography. In cases where radioiodine treatment of a toxic adenoma is indicated, attention is required, because it may trigger the Graves’ disease, as shown in this case. Every new presentation of hyperthyroidism should be investigated as a new pathology, as it may reveal a new underlying condition indicating the need for different therapeutical pathways.

Volume 93

ESE Young Endocrinologists and Scientists (EYES) 2023

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.